Use of Transgenic Mice in Carcinogenicity Hazard Assessment

Toxicologic Pathology

Volumn 32, Issue SUPPL. 1, 2004, Pages 49-52

  Jacobson Kram, David ^a   Sistare, Frank D ^a   Jacobs, Abigail C ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Carcinogenicity testing; p53; Regulatory toxicology; Tg.AC; TgrasH2; Transgenic mice

Indexed keywords

CARCINOGEN; PROTEIN P53;

ANIMAL MODEL; ANIMAL TESTING REDUCTION; ARTICLE; CANCER GENETICS; CARCINOGEN TESTING; CHEMICAL CARCINOGENESIS; ENVIRONMENTAL EXPOSURE; FOOD AND DRUG ADMINISTRATION; GENE ACTIVATION; GENE INACTIVATION; HAZARD ASSESSMENT; MOLECULAR BIOLOGY; MOUSE; MOUSE STRAIN; MOUSE STRAIN TG.AC; MOUSE STRAIN TGRASH2; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REGULATORY TOXICOLOGY; TOXICOLOGY; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ANIMALIA; MUS MUSCULUS; RODENTIA;

EID: 1842563105     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1080/01926230490424761     Document Type: Article

References (14)

1. +/- mice: evidence of chromosomal recombination. Cancer Res 60, 2831-5.
2. Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A. J., Butel, J. S., and Bradley, A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356, 215-21.
3. Hansen, L. A., and Tennant, R. W. (1994). Follicular origin of epidermal papillomas in v-Ha-ras transgenic Tg.AC mouse skin. Proc Natl Acad Sci USA 91, 7822-6.
4. ILSI/HESI Alternatives to Carcinogenicity Testing Project. (2001). Toxicol Pathol 29, 1-198.
5. International Conference on Harmonization, Expert Working Group on Safety (1997). Guidance for Industry SIB Testing for Carcinogencity of Pharmaceuticals, 〈www.fda.gov/cder/guidance/index.htm〉. ICH Geneva, Switzerland.
6. Jacobson-Kram, D., Gulezian, D., Wenk, M. L., Lanning, L. L., and Smith, G. B. (2003). Twenty six-week validation study of the Tg.rasH2 mouse test system using three carcinogens. Toxicologist 72, 1-S.
7. Leder, A., Kuo, A., Cardiff, R., Sinn, E., and Leder, P. (1990). v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid. Proc Natl Acad Sci USA 87, 9178-82.
8. Pritchard, J. B., French, J. E., Davis, B. J., and Haseman, J. K. (2003). The role of transgenic mouse models in carcinogen identification. Environ Health Perspect 111, 1-11.
9. Saitoh, A., Kimura, M., Takahashi, R., Yokoyama, M., Nomura, T., Izawa, M., Sekiya, T., Nishimura, S., and Katuski, M. (1990). Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene 5, 1195-1200.
10. Sistare, F. D., and Jacobs, A. C. (2003). Use of transgenic animals in regulatory carcinogenicity evaluations. In Alternative Toxicological Methods (H. Salem and S. A. Katz, eds.), pp. 391-412. CRC Press, Boca Raton. FL.
11. +/- Knockout mice: overview of available data. Toxicol Pathol 29, 117-27.
12. +/- Knockout mice: nature of the models. Toxicol Pathol 29, 109-16.
13. +/- mouse model in carcinogenicity testing. Toxicol Pathol 29, 147-54.
14. +/- and CD-1 mice following repeated subcutaneous injections of solutions containing antioxidants. Environ Molec Mutagen 37, 27-30.